Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending November 28, 2006. The report serves as a notification of transactions involving Directors, Persons Discharging Managerial Responsibility, or Connected Persons regarding Ordinary Shares of the Company.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory disclosure of specific share transactions rather than a financial performance report.
Material Changes
The filing details specific transactions involving the SmithKline Beecham Employee Benefit Trust ("the Trust") on November 21, 2006:
- Share Sale: 656 Ordinary shares were sold on behalf of a participant in the SmithKline Beecham Annual Investment Plan at a price of GBP 13.63 per share.
- Share Transfer: 792 Ordinary shares were transferred from the Trust to a participant in the same plan.
Director Mr. J S Heslop is noted as having an interest in the shares held in the fund, consistent with other non-US employees or former employees.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document strictly addresses compliance with Disclosure Rule 3.1.4R(1)(b) regarding director and connected person transactions.
Investor Verification Points
- Verify the total number of shares held by the SmithKline Beecham Employee Benefit Trust to assess the significance of the reported transactions.
- Confirm the current share price relative to the GBP 13.63 transaction price reported in November 2006.
- Review the full list of directors and connected persons to understand the scope of interests in the discretionary fund.